Edgestream Partners L.P. Buys Shares of 48,226 Roivant Sciences Ltd. (NASDAQ:ROIV)

Edgestream Partners L.P. purchased a new position in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 48,226 shares of the company's stock, valued at approximately $557,000.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. FMR LLC grew its position in Roivant Sciences by 5.6% during the 3rd quarter. FMR LLC now owns 49,145,056 shares of the company's stock worth $567,134,000 after purchasing an additional 2,593,910 shares in the last quarter. Rubric Capital Management LP boosted its position in Roivant Sciences by 15.0% during the second quarter. Rubric Capital Management LP now owns 23,000,000 shares of the company's stock valued at $243,110,000 after purchasing an additional 3,000,000 shares during the last quarter. DME Capital Management LP grew its stake in Roivant Sciences by 14.8% in the second quarter. DME Capital Management LP now owns 4,810,960 shares of the company's stock valued at $50,852,000 after purchasing an additional 620,470 shares in the last quarter. Loomis Sayles & Co. L P increased its position in Roivant Sciences by 13.3% in the 3rd quarter. Loomis Sayles & Co. L P now owns 3,912,205 shares of the company's stock worth $45,147,000 after purchasing an additional 458,601 shares during the last quarter. Finally, BlackBarn Capital Partners LP raised its stake in shares of Roivant Sciences by 63.1% during the 2nd quarter. BlackBarn Capital Partners LP now owns 3,100,000 shares of the company's stock worth $32,767,000 after purchasing an additional 1,199,406 shares in the last quarter. Institutional investors and hedge funds own 64.76% of the company's stock.

Roivant Sciences Stock Up 2.5 %

Roivant Sciences stock traded up $0.30 during trading hours on Friday, hitting $12.38. The stock had a trading volume of 2,218,564 shares, compared to its average volume of 5,797,968. Roivant Sciences Ltd. has a fifty-two week low of $9.48 and a fifty-two week high of $13.06. The company has a market cap of $9.01 billion, a PE ratio of 2.14 and a beta of 1.25. The company has a 50-day moving average of $11.80 and a two-hundred day moving average of $11.40.

Insider Buying and Selling at Roivant Sciences

In other Roivant Sciences news, CAO Rakhi Kumar sold 250,000 shares of the company's stock in a transaction dated Monday, September 23rd. The shares were sold at an average price of $11.89, for a total transaction of $2,972,500.00. Following the sale, the chief accounting officer now directly owns 209,322 shares of the company's stock, valued at approximately $2,488,838.58. This represents a 54.43 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Eric Venker sold 100,000 shares of Roivant Sciences stock in a transaction on Monday, October 21st. The shares were sold at an average price of $11.65, for a total value of $1,165,000.00. Following the completion of the transaction, the chief operating officer now owns 617,470 shares of the company's stock, valued at approximately $7,193,525.50. The trade was a 13.94 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 3,677,309 shares of company stock valued at $43,283,184 in the last 90 days. 7.90% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on ROIV shares. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Roivant Sciences in a research report on Thursday, September 19th. HC Wainwright reaffirmed a "buy" rating and issued a $18.00 price objective on shares of Roivant Sciences in a research note on Wednesday, November 13th. Finally, Bank of America raised their target price on Roivant Sciences from $12.00 to $12.50 and gave the company a "neutral" rating in a report on Wednesday, September 11th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $17.93.

Roivant Sciences Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.